枸杞糖肽联合拉米夫定治疗慢性乙型肝炎近期疗效

目的：探讨枸杞糖肽胶囊联合拉米夫定片治疗慢性乙型肝炎的近期疗效。方法：联合组应用枸杞糖肽胶囊30mg，pobid，联合拉米夫定片100mg，poqd，疗程6个月；对照组单用拉米夫定片，用法及疗程相同。观察两组患者治疗后的临床症状改善、肝功能好转、HBV-DNA下降、HBeAg转阴及HBeAg／抗-HBe血清转换的效果。结果：两组患者治疗后的ALT、AST、TBil、HBeAg转阴率、HBeAg／抗-HBe血清转换率、HBV—DNA转阴率及log10（HBV-DNA）水平，与治疗前比较差异有显著性（P〈0，01或P〈0．05）；治疗后的效果两组对比，联合组在ALT水平、HBeAg／抗-HBe血清转换率及log10（HBV—DNA）水平等方面优于对照组（P〈0.05）。结论：枸杞糖肽胶囊联合拉米夫定片治疗慢性乙型肝炎近期疗效显著，枸杞糖肽胶囊可以促进肝功能恢复、增加HBeAg／抗-HBe血清转换率及降低HBV—DNA水平，可以作为慢性乙型肝炎治疗的辅助药物。

Short-term Effect of Fructus Lycii Glucopeptide Combined with Lamivudine on Patients with Chronic Hepatitis B

Objective： To investigate the short-term effect offructus lycii glucopeptide combined with lamivudine on patients with chronic hepatitis B. Method ： The combination group was treated with the union offructus lycii glucopeptide （caps, 30 mg po bid） and lamivudine （tabs, 100 mg, po, qd） for a 6-month course. The controlled group was treated with lamivudine only, following the same direction and course. After the treatment, both groups were observed to evaluate their effects on the improvement of clinical symptoms and liver function, on the decrease of HBV-DNA level, on the elimination of HBeAg and on the HBeAg/anti-HBe seroconversion. Result： There were significant differences （P 〈0.01 or P 〈 0.05） in the levels of ALT, AST, TBil and log10 （HBV-DNA）, the negative-turning rate of HBeAg and HBV-DNA as well as the HBeAg/anti-HBe seroconversion rate between post-treatment and prior treatment in both groups： There were also statistical differences in the levels of ALT, log10 （HBV-DNA） and HBeAg/anti-HBe seroconversion rate between the two groups after the treatment （P 〈 0.05 ）. Conclusion： The therapeutic alliance withfructus lycii glucopeptide and lamivudine produced a notable short-term effect on the patients with chronic hepatitis B. Fructus lycii glucopeptide could promote a functional restoration of the liver, enhance HBeAg/anti-HBe seroconversion rate and decrease the HBV-DNA level and therefore could be used as an ancillary drug in the therapy of chronic hepatitis B.